Clinical trials: Von Willebrand Factor Deficiency
Factor VIII Deficiency
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
Primary Objective: To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: To evaluate the efficacy of BIVV001 as a prophylaxis treatment.
- Trial name
- XTEND-1 (NCT04161495)
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 47 sites in United States, Argentina and 17 more
- Volunteers
- 159 people
- Sponsor
- Bioverativ, a Sanofi company
Coagulation Disorder, Blood, Prolonged APTT
External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
Prolonged activated partial thromboplastin time (APTT) is a frequent laboratory finding that may reflect a broad spectrum of underlying conditions, ranging from benign laboratory abnormalities to clinically relevant hemostatic…
- Trial name
- APTTO-EXT (NCT07418099)
- Testing
- Clot waveform analysis-based risk stratification (APTTO models)
- Where
- 16 sites in Spain
- Volunteers
- 1,500 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Primary Haemostasis Disorder in Cardiac Surgery Patients
Relation Between the Value of Platelet Clot Stiffness (PCS) Obtained by Sonorheometric Method of Delocalized Hemostasis (QUANTRA®), and the Presence of a Disorder of Primary Hemostasis, in Cardiac Surgery Patients. PLAQUA-Study
The goal of this study is to determine whether the Platelet Clot Stiffness (PCS) measured by QUANTRA® is predictive of an abnormality in primary haemostasis intraoperatively in cardiac surgery performed under extracorporeal…
- Trial name
- PLAQUA (NCT06585930)
- Testing
- Blood sample
- Where
- Reunion
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Hematologic Disorder, Bleeding Disorder
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly.
- Conditions
- Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia
- Trial name
- NCT04398628
- Where
- 76 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- American Thrombosis and Hemostasis Network
Von Willebrand Factor, Deficiency
Low Von Willebrand in Ireland Cohort Study
The Low Von Willebrand in Ireland Cohort (LoVIC) study focuses on the bleeding phenotype and biological mechanisms underlying low Von Willebrand Factor (VWF) levels.
- Trial name
- LOVIC (NCT03167320)
- Where
- Ireland
- Volunteers
- 400 people
- Sponsor
- St. James's Hospital, Ireland
Von Willebrand Disease
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Von Willebrand Disease (VWD) is defined as an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of…
- Trial name
- PERICOLL (NCT02792205)
- Testing
- Non interventional study
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Von Willebrand Disease
Willebrand International Non-interventional Global Surveillance
Collect information about WILLFACT or WILFACTIN in their real life clinical use and identify the therapeutic practices in an international environment.
- Trial name
- NCT01949220
- Where
- 18 sites in Belgium, Czechia and 5 more
- Volunteers
- 80 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Von Willebrand Factor Deficiency
Low VW Activity in Adolescent HMB
This is a research study for patients diagnosed with heavy menstrual bleeding (HMB) and low Von Willebrand Factor (VWF). Menstruation, also known as a period, is the regular discharge of blood and tissues from the uterus.
- Trial name
- Low VWF (NCT02933411)
- Testing
- Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Baylor College of Medicine
Von Willebrand Disease
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.
- Trial name
- NCT00555555
- Testing
- Alphanate SD/HT
- Volunteers
- 4 people
- Sponsor
- Grifols Biologicals, LLC